Understanding of the role of herpes simplex virus type 2 (HSV-2) genes and their corresponding gene products in appropriate models of viral pathogenesis has lagged behind similar studies performed on HSV-1 counterparts. The vaginal murine and guinea pig models of herpetic disease provide an opportunity to study the contribution of HSV-2 gene products during both the acute and latent phases of disease. In particular, the guinea pig model mimics that of human disease in that one can observe acute disease and subsequent reactivation from latency. Despite such a model, few HSV-2 genes have been characterized for their role in genital disease. Understanding which gene products are important for attenuation at the level of acute and latent disease is necessary if one is to design an effective live, attenuated vaccine.
To date, studies using the guinea pig model have characterized the role of only a few HSV-2 loci, the viral thymidine kinase (TK) (1) , the large subunit of ribonucleotide reductase (27) , and the latency-associated transcript region (11, 28, 31) . Studies of HSV-2 mutants in murine models have included the characterization of the HSV-2 TK (15), US2 and US3 (6) , virion host shut-off (19) , and glycoprotein C (9) genes. In this report, we characterize the role the HSV-2 UL24 gene product in both murine and guinea pig vaginal models of disease.
The HSV-2 UL24 gene product was recently shown to be a 32-kDa virion structural protein (5) , but currently no information is available describing the role of HSV-2 UL24 during in vitro infection or in viral pathogenesis in vivo. DNA sequence analysis has revealed that UL24 homologs are present throughout the Herpesviridae family. The herpes simplex virus type 1 (HSV-1) UL24 gene product was shown to be a 30-kDa nucleus-associated protein (16) that is not required for growth in cultured cells (7) . The UL24 homolog identified in bovine herpesvirus type 1 (BHV-1) was shown to have a transcription profile similar to that of HSV-1 UL24. Deletion of the BHV-1 UL24 open reading frame (ORF) had little effect on viral replication in vitro (30) .
Although the function(s) of the UL24 protein is not known, mutation of the HSV-1 gene results in the development of a syncytial plaque-forming phenotype following infection of certain cell types in vitro (7, 8, 23) . Thus, the UL24 protein may regulate fusogenic activity during HSV infection. There are a number of different HSV gene products whose alteration or mutation appears to affect fusogenic activity during infection. The in vivo significance of gene products that modulate fusion is not yet understood. Studies using HSV-1 UL24 point mutants in a murine ocular disease model suggested that the HSV-1 UL24 gene product was important for peripheral replication in corneal tissue, acute replication in sensory ganglia, and reactivation from explanted mouse ganglia (7) .
We are interested in studying the contribution of HSV-2 gene products to viral replication and virulence. In this study, a UL24 ␤-glucuronidase (UL24-␤gluc) insertion mutant and the corresponding repaired virus (UL24R) were constructed and characterized for the ability to (i) replicate in three different cell lines in vitro and (ii) cause disease after intravaginal inoculation in both murine and guinea pig disease models.
MATERIALS AND METHODS
Viruses and cells. African green monkey kidney (Vero), human foreskin fibroblast (HFF), and SK-N-SH neuroblastoma cell lines were grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, 100 units/ml of penicillin, and 100 g/ml of streptomycin sulfate. Cells infected with virus were grown in Dulbecco's modified Eagle's medium containing 2% serum and antibiotics.
HSV-2 strain 186 was propagated and titered on Vero cells and used as the parental virus for these studies.
Construction and isolation of UL24-〉gluc and UL24R. The region containing and flanking the UL24 gene (Fig. 1 , speckled box) was amplified by PCR from wild-type HSV-2 strain 186 DNA and cloned into the PCR-Blunt II-TOPO vector (Invitrogen, Carlsbad, CA). The region containing the HSV-2 186 UL23 and UL24 genes was sequenced and compared to that of HSV-2 HG52 and HSV-1 17 using Clustal W alignment.
UL24-␤gluc was constructed by inserting a ␤-glucuronidase cassette (Clonetech, Palo Alto, CA) into the conserved BglII site of the HSV-2 186 UL24 ORF (Fig. 1) . Briefly, the plasmid containing the UL24 gene was digested at the single BglII site and a ␤-glucuronidase cassette with BamHI ends was inserted as depicted in Fig. 1 . The ␤-glucuronidase cassette (approximately 2.8 kb) comprises the ␤-glucuronidase gene (approximately 1.9 kb), simian virus 40 promoter and simian virus 40 polyadenylation sequences. The plasmid containing the disrupted UL24 gene was linearized and transfected into Vero cells that were subsequently infected with HSV-2 186 (25) . Transfection/infection stocks were plated in the presence of the chromogenic substrate 5-bromo-4-chloro-3-indolyl-␤-D-glucuronide (X-Gluc) and blue plaque mutants were selected from the background of white parental 186 viruses as previously described (10) . Blue plaques representing viral recombinants were plaque purified three times, and one plaque, UL24-␤gluc, was selected for further study.
The unaltered, TOPO-cloned DNA fragment containing the HSV-2 186 UL24 gene was used to repair UL24-␤gluc. This fragment was transfected into Vero cells that were subsequently infected with UL24-␤gluc. White, nonsyncytial plaques were purified and a single UL24-repaired virus, UL24R, was selected for further study.
Southern blot analysis. Viral DNA was isolated from partially purified virions, digested with restriction enzymes (BamHI, NcoI, and SacI), and electrophoresed through agarose gels. The DNAs were blotted to positively charged nylon membranes and hybridized to either a 600-bp HSV-2 fragment (UL24 5Ј probe) or ␤-glucuronidase-specific sequences (␤-glucuronidase probe) (Fig. 1) . Doublestranded DNA probes were radiolabeled with [␣-33 P]dCTP and viral DNA fragments hybridizing to the probes were detected by autoradiography.
In vitro viral replication and viral plaque morphology. Three cell types, Vero, HFF, and SK-N-SH, were infected with either HSV-2 186, UL24-␤gluc, or UL24R at a multiplicity of infection (MOI) of 0.01 or 5.0. Photographs were taken to document cytopathic effect. Infected cells were harvested at the indicated time points, subjected to three cycles of freeze-thawing, processed in a cup-horn sonicator for approximately 15 s, and clarified by low-speed centrifugation (2,000 ϫ g). A commercial enzyme-linked virus-inducible system (20) (ELVIS; Diagnostic Hybrids, Inc., Athens, OH) in a 96-well format was used to estimate the titer of all growth kinetics samples. Using this system, quantitation of viral titers is typically performed by counting blue cell-forming units (BFU). Previous studies revealed that the number of BFU/ml closely approximates the number of PFU/ml as determined by plaque assay (20) . Since we have consistently observed a positive correlation between ␤-galactosidase levels, BFU, and PFU, a soluble ␤-galactosidase assay was employed to estimate the amount of virus present in each sample (14) .
In brief, infected cell samples and a positive control sample containing a known amount of virus were serially diluted in serum-free medium and incubated for 1 hour at 37°C, after which 75 l was transferred to a well of the ELVIS plate containing 75 l of serum-free medium. Following a second 1 hour of incubation at 37°C, 75 l of ELVIS replacement medium was added to each well and plates were placed in a 37°C CO 2 incubator for 16 to 18 h. Medium was replaced with 50 l of 1% Triton X-100, and plates were frozen at Ϫ70°C for a minimum of 2 h. Plates were thawed and 50 l of 2X chlorophenol red-␤-D-galactopyranoside (CPRG, 16 mM), 0.12 M Na 2 HPO 4 , 0.08 M NaH 2 PO 4 , 0.02 M KCl, 2 mM MgSO 4 and 0.01 M ␤-mercaptoethanol, pH 7.8, substrate was added followed by 1 to 3 h of incubation at 37°C. Optical density (OD) values for the various sample dilutions were determined at 570 nm. Values obtained for the infected cell samples were utilized to estimate viral titers by comparison with a standard curve generated from the positive control sample results.
Plaque reduction assay. Plaque reduction assays were performed as previously described (26) Five days prior to virus challenge, all mice received 2.0 mg Depo-Provera (Upjohn Company, Kalamazoo, MI) subcutaneously in the scruff of the neck to synchronize their estrous cycles and to increase their susceptibility to HSV-2 vaginal infection (15) . For infection, mice were anesthetized and the vaginas were swabbed with a sterile Dacron polyester tip applicator (Puritan, Guilford, ME) prewet in phosphate-buffered saline to remove any associated mucus. Mice were subsequently inoculated intravaginally with the indicated doses of either wild-type HSV-2 strain 186, UL24-␤gluc, or UL24R. Virus was instilled into the vaginal vault with the aid of a micropipettor (0.01 ml/dose). The mice were monitored daily for 4 weeks for symptoms of viral infection and mortality.
Mice were scored for signs of disease using the following scale: 0, no symptoms; 1, vaginal erythema; 2, vaginal erythema and edema; 3, vaginal herpetic lesions; 4, unilateral paralysis; and 5, bilateral paralysis or death. The mean severity index was determined by taking the mean score of all mice within a group. All mice that were bilaterally paralyzed or showed signs of severe illness and/or distress (fever or weight loss) were immediately subjected to euthanasia.
Guinea pig model of herpetic disease. Hartley albino out-bred female guinea pigs (250 to 350 g) were obtained from Charles River Laboratories (Kingston, N.Y.). Animals were prepared for intravaginal inoculation by first swabbing the region with a calcium alginate swab prewet in phosphate-buffered saline, followed by swabbing with a dry swab to remove vaginal mucus that might interfere with virus uptake. The desired dose of virus was formulated in 100 l of phosphate-buffered saline and slowly instilled into the vaginal vault with a 1-ml syringe fitted with 0.5 inch (ca. 1.5 cm) of narrow butterfly tubing.
Disease scoring was performed as previously described by the method of Stanberry et al. (21) . Acute disease was scored between days 3 and 10 postinoculation. The mean lesion score represents the average disease score of all surviving animals on that day of scoring. Recurrent disease was scored by counting lesions each day between days 15 and 56 postinoculation. The average lesions per animal in the group were expressed cumulatively over the noted time period.
Animals were constantly observed for signs of severe disease, including paralysis and central nervous system involvement. Mortality values reflect animals that were sacrificed due to distress.
Detection of HSV-2 DNA in guinea pig dorsal root ganglia. Sacral dorsal root ganglia (six per animal) were dissected at the termination of the experiment and weighed and the viral DNA was extracted using a QIAamp DNA mini kit (QIAGEN). Real-time PCR was performed on extracted DNA samples. A standard curve was constructed for each experiment using purified plasmid containing HSV-2 glycoprotein D gene sequences. Data were normalized using probes specific for guinea pig lactalbumin DNA in order to correct for variable amounts of neural material in the dissected ganglia.
RESULTS

Construction and isolation of UL24-␤gluc and UL24R
. The UL24-␤gluc insertion mutant was isolated as described in the Materials and Methods. Based on the predicted amino acid FIG. 7 . In vivo mouse data, including (a) mortality curves, (b) lesion scores, and (c) disease progression. Mice were anesthetized, vaginas were swabbed, and the indicated dose (PFU) of each virus was gently instilled into the vaginal vaults with the aid of a micropipettor. Scoring: 0, no symptoms; 1, vaginal erythema; 2, vaginal erythema and edema; 3, vaginal herpetic lesions; 4, unilateral paralysis; and 5, bilateral paralysis or death. The mean severity index was determined by taking the mean score of all mice within a group (error bars represent the standard deviation of the mean).
sequence of HSV-2 UL24 (281 amino acids), insertion into the BglII site of the UL24 ORF (Fig. 1) should result in a truncated UL24 polypeptide lacking the final 100 C-terminal amino acid residues (i.e., Ser 182 to Glu 281) of the full-length UL24 protein. The insertion mutation was designed so that the overlapping UL23 TK gene transcript would not be disrupted but, conversely, all six potential UL24 transcripts (shown to be expressed from the HSV-1 UL24 gene) (2) would be disrupted.
The nucleotide sequence of HSV-2 186 in the region containing the 5Ј-overlapping UL23 and UL24 ORFs was sequenced and compared to that of HSV-1 17 and HSV-2 HG52 via Clustal W alignment (Fig. 2) . The 186 sequence was nearly identical to that of HG52 and had high identity to HSV-1 17. Although we have not mapped the transcripts for HSV-2 186 UL24, the genetic layout and sequence relatedness suggest that expression of HSV-2 186 UL24 would not be significantly different from that of HSV-1. Furthermore, for this study, we constructed a single insertion mutation clearly within the UL24 ORF, and no attempt is made to dissect a role for any particular UL24 transcript.
A cloned DNA fragment containing the HSV-2 186 UL24 gene was used to repair UL24-␤gluc and generate UL24R.
Analysis of recombinant viral genomes. Figure 1 is a schematic representation of the genomic structure for the region encoding the UL24 gene. Restriction maps are provided for parental HSV-2 strain 186 and UL24-␤gluc. The locations of two DNA probes utilized in Southern analysis are indicated ( Fig. 1 ; ␤-gluc and UL24 5Ј probes). Viral DNAs were analyzed by Southern blotting (Fig. 3 ) to confirm that they had the expected genomic structures. HSV-2 186, UL24-␤gluc, and UL24R DNAs were digested with BamHI, NcoI, or SacI and probed with a 600-base-pair fragment containing 3Ј UL23 and 5Ј UL24 sequences (UL24 5Ј probe, Fig. 1 ). Based on the restriction map in Fig. 1 , HSV-2 186 and UL24R digested DNAs should yield fragments of 3.3 and 4.1 kb, 4.5 kb, and 4.4 kb after digestion with BamHI, NcoI, and SacI, respectively. Insertion of the ␤-glucuronidase cassette into the BglII site of the UL24 gene would introduce new restriction sites resulting in fragments of 3.3 and 6.7 kb, 4.0 kb, and 6.9 kb after digestion with BamHI, NcoI, and SacI, respectively. The predicted hybridization patterns were observed for all three viruses.
Using ␤-glucuronidase DNA sequences as a probe (Fig. 1 , ␤-gluc probe), UL24-␤gluc DNA fragments of 6.7 kb (BamHI), 4.0 kb, 2.8 kb, and 0.1 kb (NcoI), and 6.9 kb (SacI) were observed, as predicted (data not shown). As expected, the ␤-glucuronidase probe did not hybridize with any 186 or UL24R DNA fragments.
In vitro cytopathic effect and in vitro replication. The cytopathic effect after infection of three different cell types with either 186, UL24-␤gluc, or UL24R was examined. Vero, HFF, and SK-N-SH cell monolayers displayed extensive syncytium formation after infection with UL24-␤gluc (Fig. 4) . Nonsyncytial plaques were not observed. No syncytia formed after infection with either 186 or UL24R.
The ability of the viruses to replicate in vitro was analyzed. Vero, HFF, or SK-N-SH cells were infected at either low (0.01) or high (5.0) MOI. Figure 5a shows the total virus yield obtained at 18 h postinfection with an MOI of 5.0. All three viruses replicated to similar titers (Ϸ10 6 PFU) in each of the cell types.
Low MOI (0.01) was utilized to examine the ability of the three viruses to replicate and spread in the three cell types (Fig. 5b, c, and d) . Regardless of the cell type employed, all three viruses replicated and spread with comparable kinetics, as indicated by the increasing titers. The results shown in Fig. 5 indicated that insertion of the ␤-glucuronidase cassette into the BglII site of the UL24 gene did not drastically affect the ability of the virus to replicate in vitro. Combined with the plaque morphology data, these results suggest that the C-terminal one-third of the UL24 gene product was important, either directly or indirectly, in modulating fusion events in HSV-2-infected cells but that the fulllength UL24 gene product was not required for replication in the cell types tested.
TK function (sensitivity to acyclovir). The proximity of the UL24 and UL23 (TK) genes created the possibility that mutation of the UL24 gene could affect the expression of the TK gene (Fig. 2 ). This presented a major concern in previous studies when trying to determine the separate roles of the TK or UL24 genes in viral replication, particularly in viral pathogenesis (4, 8, 12, 13, 18 ). The insertion mutation within UL24-␤gluc was such that it should not have any deleterious effects on the expression and therefore the function of the HSV-2 TK gene. The lack of an effect on HSV-2 TK function was demonstrated by examination of the sensitivity of the three viruses to increasing concentrations of acyclovir (Fig. 6 ). All three viruses showed a similar 50% inhibitory concentration of approximately 3 M. Hence, this result strongly suggested that the TK activity (phosphorylation of acyclovir) was similar for all three viruses and that any properties or phenotypes observed for UL24-␤gluc are independent of TK activity.
Pathogenesis in mice.
A murine intravaginal infection model was employed to evaluate the ability of UL24-␤gluc to cause morbidity and mortality in vivo (Fig. 7) . Survival curves (Fig.  7a) indicated that HSV-2 186 killed 100% of mice infected with either 250 or 1.25 ϫ 10 4 PFU and UL24R killed 70% and 100% at 250 and 1.25 ϫ 10 4 PFU, respectively. In contrast, a total of 80 animals (10 per group) were inoculated with various doses of UL24-␤gluc, ranging from 250 to 10 5 PFU, and all of the animals survived during the 4-week observation period following viral inoculation.
Similar results were observed when measuring lesion formation or disease progression (based on severity score; see Materials and Methods). Lesion formation was observed in mice infected with either 186 or UL24R at either dose (Fig. 7b) . One hundred percent of the infected animals showed herpetic lesions for both 186 groups and the high-dose UL24R group by day 10. Eighty percent of the low-dose UL24R group presented with lesions. In contrast, very few of the 80 UL24-␤gluc-inoculated animals presented with lesion formation. A small amount of lesion formation was scored at day 10 in two of the eight UL24-␤gluc groups.
Disease severity scores mimicked lesion formation (Fig. 7c) . The severity of disease was delayed and reduced in all of the UL24-␤gluc-infected mice, where average disease scores ranged from no symptoms to mild vaginal erythema.
Pathogenesis in guinea pigs. The guinea pig intravaginal model for HSV-2 is well established and has been shown to mimic both the acute and latent phases of human herpetic disease (21) . Since HSV-2 186 was shown to have a relatively low LD 50 in guinea pigs, we decided to perform the guinea pig experiments with an inoculum that was approximately the LD 50 of strain 186. The mortality data showed that HSV-2 186 killed 80% of the guinea pigs at a dose of 3 ϫ 10 3 PFU by day 30, whereas UL24-␤gluc, administered at a similar dose, did not kill any animals (Fig. 8a) . We observed the guinea pigs for symptoms of acute disease during the first 8 days after intravaginal inoculation (before the 186-infected animals began to die). Acute disease (Fig. 8b) was generally higher (mean lesion score, Ϸ2.1) for 186-infected animals, whereas UL24-␤gluc-infected animals showed only low-level indications of infection (mean lesion score, Ϸ0.5).
The UL24-␤gluc-infected animals were followed from days 15 to 50 postinfection for signs of reactivation from latency (Fig. 8c) . The appearance of lesions in some animals was indicative that the UL24-␤gluc mutant could establish latency in the dorsal root ganglia of intravaginally infected guinea pigs and that the mutant virus could reactivate to form herpetic lesions. Furthermore, real-time quantitative PCR performed on ganglia removed on day 50 postinfection from the 10 UL24-␤gluc animals indicated that at least 7/10 (70%) of the UL24-␤gluc-infected guinea pigs contained detectable HSV-2 DNA in their ganglia. The results suggested that UL24-␤gluc was able to establish a latent infection in guinea pig dorsal root ganglia that could reactivate to produce lesions after the resolution of the acute disease phase. It was not possible to directly compare the levels of reactivation to wild-type virus in this experiment due to the high mortality rate observed with strain 186. Further studies will be required to accurately determine if the number of genome copies per ganglion differs between UL24-␤gluc-and 186-infected animals.
DISCUSSION
A number of herpesvirus genes have been shown to be nonessential for growth in cultured cells. However, when viral mutants were tested in certain animal models, a number of these genes proved to be important in promoting viral replication and disease in vivo. (reviewed in references 22, 24, and 29) . The studies presented here provide new information of the contribution of the UL24 gene in herpes simplex virus pathogenesis. We described the isolation of a UL24 insertion mutant that is viable in vitro yet shows significant attenuation in two different small-animal disease models.
Analysis of the role of the UL24 gene in the viral life cycle in vitro and in vivo has been complicated by the fact that certain mutations in UL24 can affect the expression of the overlapping UL23 (TK) gene (4, 8, 12, 13, 18) . We addressed these concerns by measuring the sensitivity of UL24-␤gluc to acyclovir, the substrate for viral TK. The results demonstrate that the ␤-glucuronidase cassette, inserted at the BglII site used to disrupt the UL24 ORF, had no obvious effect on the expression or function of the HSV-2 TK as measured by sensitivity to acyclovir.
Our results suggest that the full-length HSV-2 UL24 protein is not required for viral replication in vitro. However, insertion mutagenesis of the UL24 gene resulted in a syncytial plaque phenotype in the three cell types tested. It is likely that the C-terminal one-third of the UL24 gene product is important, either directly or indirectly, in modulating fusion events in the infected cell but that this region was not essential for viral replication in vitro.
The role of the UL24 gene in vivo was assessed by intravaginal inoculation of parental and recombinant viruses into BALB/c mice and Hartley guinea pigs. An HSV-2 UL24 mutant was avirulent in mice at doses up to at least 400 times the parental virus LD 50, the highest dose tested. Intravaginal infection of mice with a UL24 mutant resulted in delayed disease kinetics and minimal disease progression, including lesion formation. Low levels of acute herpetic disease with no associated mortality were observed in guinea pigs following intravaginal infection with the UL24 mutant at a dose that was at least equivalent to the LD 50 of the parental virus.
Our studies showed that UL24-␤gluc was able to establish latency in the dorsal root ganglia of intravaginally infected guinea pigs and could reactivate to yield characteristic herpetic lesions, albeit at lower levels than those observed for wild-type HSV-2 strains (data not shown). Previously, HSV-1 UL24 mutants examined in a murine ocular virus challenge model suggested a role for UL24 in the establishment and reactivation from latency in mouse ganglia (7) .
The similarities and differences between HSV-1 and HSV-2 UL24 mutants with respect to latency are difficult to assess. HSV-1 UL24 mutants were significantly impaired for their ability to replicate in trigeminal ganglia and in their ability to reactivate from latency, as determined by cocultivation and dissociation of ganglia. Similarly, our studies suggested that the UL24-␤gluc was impaired for the ability to replicate and/or spread in the guinea pig central nervous system, since no mortality or morbidity (paralysis) was observed at the dose tested. However, UL24-␤gluc was able to establish latency in guinea pig sacral ganglia in that 7 of 10 animals were positive for HSV-2 DNA sequences 50 days postinoculation. The HSV-2 UL24 mutant could reactivate from latency in the guinea pig model, but both the number of lesions and severity of disease never approached that of other wild-type HSV-2 strains (186 and MS) that we have tested (data not shown).
Further studies of the HSV-2 UL24 protein will be necessary to understand why UL24-␤gluc replication in cell culture was similar to that of wild-type virus yet was clearly attenuated with respect to disease in both the murine and guinea pig models. The guinea pig model should prove valuable in evaluating both the prophylactic and therapeutic potential of UL24 mutants as attenuated vaccine candidates.
